Daily Bulletin

Men's Weekly

.

Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision
  • The new proof of mechanism trial in ulcerative colitis had its first patient dosed in New Zealand
  • In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via rectal administration

SEONGNAM, South Korea, June 2, 2021 /PR...

Read more: Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in...

Business News

How to Extend the Lifespan of Your Conveyor System

It’s easy to forget your conveyor is even there, until it stops. And when it does, you’re in a world of delayed orders, unexpected downtime, and one very expensive headache. But the good news is tha...

Daily Bulletin - avatar Daily Bulletin

Virtual CFO Hiring Checklist: 10 Expert Tips in Australia

Hiring a Virtual CFO (VCFO) is no longer just reserved for large corporations. In today’s business environment, where agility, compliance, and strategic foresight are essential, Australian startups...

Daily Bulletin - avatar Daily Bulletin

Top Mistakes to Avoid When Hiring Office Removalists in Perth

Moving a workplace is more than shifting workstations and computers; it is a complex project that can affect staff morale, customer service and revenue if it goes off-track. Perth’s commercial prope...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals